Despite significant advancements in multiple myeloma (MM) treatment, high-risk (HR) and ultrahigh-risk (uHR) populations remain underserved, with poorer outcomes and shorter survival.

Read More> https://multiplemyeloma.pocn.com/treatment/advancing-care-for-high-risk-myeloma-tailored-strategies-and-innovative-therapies/